In March, ResApp announced to have completed the initial integration of ResAppDx-EU into Coviu’s telehealth platform and that ResApp and Coviu had agreed upon a per test fee (range of $ 5-10 per test) for the use of ResAppDx-EU. Meanwhile, ResApp also executed Joint Development Agreement with Phenix Health for integration of ResAppDx-EU into Phenix’s Australian telehealth platform, expected to go live before FY20 ends.

For the full article please visit: https://kalkinemedia.com/au/blog/evolution-and-expansion-of-telehealth-in-australia-1st-rap-icr